trial · primary record
Asciminib
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 21 |
| Primary completion | 2028-10-13 |
| Primary endpoint | Incidence of dose limiting toxicity (DLT) |
| Registry ID | NCT07914166 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:58:34.063Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07914166
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Asciminib · compound